avapritinib
Showing 1 - 9 of 9
Avapritinib in Chinese Gastrointestinal Stromal Tumor in Real
Not yet recruiting
- Gastrointestinal Stromal Tumors
- Avapritinib
- Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 16, 2022
Gastrointestinal Stromal Tumors, GIST Trial (Avapritinib, midazolam)
Not yet recruiting
- Gastrointestinal Stromal Tumors
- GIST
- Avapritinib
- midazolam
- (no location specified)
Jul 20, 2022
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Tumor
Approved for marketing
- Advanced Systemic Mastocytosis
- +3 more
- Avapritinib
- (no location specified)
Oct 5, 2021
Solid Tumor, Unspecified, Child, Relapsed Solid Tumor, CNS Tumor Trial in Worldwide (avapritinib)
Recruiting
- Solid Tumor, Unspecified, Child
- +2 more
- avapritinib
-
Phoenix, Arizona
- +12 more
Jul 19, 2022
GIST Trial (Avapritinib)
Approved for marketing
- GIST
- Avapritinib
- (no location specified)
Jul 23, 2020
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Tumor
Active, not recruiting
- Advanced Systemic Mastocytosis
- +3 more
- Avapritinib
-
Stanford, California
- +31 more
Mar 25, 2022
Indolent Systemic Mastocytosis Trial in Worldwide (Avapritinib, Placebo)
Active, not recruiting
- Indolent Systemic Mastocytosis
- Avapritinib
- Placebo
-
Birmingham, Alabama
- +48 more
Jan 19, 2022
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia Trial
Active, not recruiting
- Aggressive Systemic Mastocytosis
- +3 more
- Avapritinib
-
Stanford, California
- +10 more
Mar 25, 2022